KAKKIS EMIL D

Form 4 April 19, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

Check this box if no longer

subject to Section 16. Form 4 or

Form 5 obligations may continue. See Instruction

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person * KAKKIS EMIL D

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC., 60

LEVERONI COURT

(Street)

(State)

04/19/2018

NOVATO, CA 94949

2. Issuer Name and Ticker or Trading

Symbol

Ultragenyx Pharmaceutical Inc. [RARE]

3. Date of Earliest Transaction (Month/Day/Year)

4. If Amendment, Date Original

04/19/2018

Filed(Month/Day/Year)

3.

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per

response...

0.5

5. Relationship of Reporting Person(s) to

Issuer

below)

(Check all applicable)

_X__ Director 10% Owner X_ Officer (give title Other (specify

President & CEO

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if Security (Instr. 3)

(Month/Day/Year)

(Zip)

TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

4. Securities

5. Amount of Securities Beneficially Owned Following Reported

Form: Direct (D) or Indirect (I) (Instr. 4)

D

6. Ownership 7. Nature of Indirect Beneficial Ownership (Instr. 4)

(A) Transaction(s) (Instr. 3 and 4) (D) Price

Code V Amount 3,429 \$0 452,384 (2) (1)

> 2,559,741 I

By Emil Kakkis and Jenny

Soriano Living Trust, dated June

18, 2009

Common Stock

Common

Stock

(City)

Edgar Filing: KAKKIS EMIL D - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. | | 6. Date Exerc | cisable and | 7. Tit | le and | 8. Price of |
|-------------|-------------|---------------------|--------------------|---------|---------|----------|---------------|-----------------|--------|-------------|-------------|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transa | ctionNu | mber | Expiration D | ate | Amou | ınt of | Derivative |
| Security | or Exercise | | any | Code | of | | (Month/Day/ | Year) | Unde | rlying | Security |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. | 8) De | rivative | e | | Secur | rities | (Instr. 5) |
| | Derivative | | | | Sec | curities | | | (Instr | . 3 and 4) | |
| | Security | | | | Ac | quired | | | | | |
| | | | | | (A) | or or | | | | | |
| | | | | | Dis | sposed | | | | | |
| | | | | | of (| (D) | | | | | |
| | | | | | (In: | str. 3, | | | | | |
| | | | | | 4, a | and 5) | | | | | |
| | | | | | | | | | | Amaunt | |
| | | | | | | | | | | Amount | |
| | | | | C- 1- | | | | Expiration Date | Title | or Namel | |
| | | | | | | | | | | | |
| | | | | | 37 (A) | (D) | | | | of | |
| | | | | Code | V (A) | (D) | | | | Shares | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|--|---------------|-----------|--------------------|-------|--|--|--|
| coporting of the common control of the control of t | Director | 10% Owner | Officer | Other | | | |
| KAKKIS EMIL D C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO, CA 94949 | X | | President & CEO | | | | |

Signatures

/s/ Ruben A. Garcia, attorney-in-fact 04/19/2018

**Signature of Reporting Person Dat

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date.
- (2) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2